Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0AP9T
|
|||
Former ID |
DAP000451
|
|||
Drug Name |
Cefotetan
|
|||
Synonyms |
Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
Therapeutic Class |
Antibiotics
|
|||
Company |
AstraZeneca
|
|||
Structure |
Download2D MOL |
|||
Formula |
C17H17N7O8S4
|
|||
Canonical SMILES |
CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O
|
|||
InChI |
1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1
|
|||
InChIKey |
SRZNHPXWXCNNDU-RHBCBLIFSA-N
|
|||
CAS Number |
CAS 69712-56-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9103, 7847326, 7978881, 11051543, 11466501, 11467621, 11486281, 15359621, 34717168, 46506572, 48020449, 48020450, 48095951, 48244839, 48415722, 49699096, 50124222, 50186741, 56463651, 57313480, 92125572, 92719732, 93302793, 93374658, 93578304, 103594731, 103914470, 104301116, 121363243, 124766176, 124800749, 126628099, 136199027, 137156467, 137249718, 141754331, 144204232, 152035519, 162176887, 162258056, 163409419, 164788214, 175611876, 179116605, 184545873, 184546368, 185985468, 196378900, 226443050, 241122609
|
|||
ChEBI ID |
CHEBI:3499
|
|||
ADReCS Drug ID | BADD_D00392 | |||
SuperDrug ATC ID |
J01DC05
|
|||
SuperDrug CAS ID |
cas=069712567
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bacteroides was decreased by Cefotetan. | |||
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Cefotetan (adjusted p-values: 5.85E-06). | |||
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Cefotetan (adjusted p-values: 6.79E-06). | |||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Cefotetan (adjusted p-values: 6.45E-07). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Cefotetan (adjusted p-values: 1.95E-06). | |||
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Odoribacter splanchnicus was decreased by Cefotetan (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Cefotetan (adjusted p-values: 2.73E-07). | |||
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides merdae was decreased by Cefotetan (adjusted p-values: 4.93E-07). | |||
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Prevotella copri was decreased by Cefotetan (adjusted p-values: 3.36E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium adolescentis was decreased by Cefotetan (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Collinsella aerofaciens was decreased by Cefotetan (adjusted p-values: 9.77E-04). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eggerthella lenta was decreased by Cefotetan (adjusted p-values: 1.09E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Escherichia was decreased by Cefotetan. | |||
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli ED1a was decreased by Cefotetan (adjusted p-values: 5.24E-06). | |||
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli IAI1 was decreased by Cefotetan (adjusted p-values: 4.93E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Erysipelatoclostridium ramosum was decreased by Cefotetan (adjusted p-values: 9.46E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Blautia obeum was decreased by Cefotetan (adjusted p-values: 1.78E-06). | |||
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium was not significantly changed by Cefotetan. | |||
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium difficile was increased by Cefotetan. | |||
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridium perfringens was decreased by Cefotetan (adjusted p-values: 5.51E-07). | |||
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Coprococcus comes was decreased by Cefotetan (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Dorea formicigenerans was decreased by Cefotetan (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Enterocloster bolteae was decreased by Cefotetan (adjusted p-values: 2.60E-05). | |||
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium eligens was decreased by Cefotetan (adjusted p-values: 1.81E-04). | |||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Cefotetan (adjusted p-values: 2.71E-04). | |||
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lacrimispora saccharolytica was decreased by Cefotetan (adjusted p-values: 6.79E-07). | |||
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia hominis was decreased by Cefotetan (adjusted p-values: 2.03E-05). | |||
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia intestinalis was decreased by Cefotetan (adjusted p-values: 1.56E-04). | |||
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus bromii was decreased by Cefotetan (adjusted p-values: 1.30E-05). | |||
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus torques was decreased by Cefotetan (adjusted p-values: 7.87E-04). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Increase | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterococcus was increased by Cefotetan. | |||
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Lactobacillus was not significantly changed by Cefotetan. | |||
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus parasanguinis was decreased by Cefotetan (adjusted p-values: 5.51E-07). | |||
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus salivarius was decreased by Cefotetan (adjusted p-values: 1.67E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Veillonella parvula was decreased by Cefotetan (adjusted p-values: 5.04E-06). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Target Info | Binder | [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
REF 2 | The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J Antimicrob Chemother. 1985 Mar;15(3):319-26. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.